Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Sevko A"'
Publikováno v:
Engineering Biology, Vol 8, Iss 2-3, Pp 31-40 (2024)
Abstract Living cures are cell‐based, programmable therapies that integrate the latest learnings in immunology and synthetic biology. Although Adoptive Cell Therapies (ACTs) have transformed the treatment landscape of haematological malignancies by
Externí odkaz:
https://doaj.org/article/95517735e34a4048a8450c3b73c78a70
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0689003904cd4129bf16310410f14c27
Publikováno v:
Engineering Biology; Jun-Sep2024, Vol. 8 Issue 2, p31-40, 10p
Autor:
Victoria E. Anderson, Sara S. Brilha, Anika M. Weber, Annette Pachnio, Guy E. Wiedermann, Sumaya Dauleh, Tina Ahmed, George R. Pope, Laura L. Quinn, Roslin Y. Docta, Adriano Quattrini, Siobhan Masters, Neil Cartwright, Preetha Viswanathan, Luca Melchiori, Louise V. Rice, Alexandra Sevko, Claire Gueguen, Manoj Saini, Barbara Tavano, Rachel J.M. Abbott, Jonathan D. Silk, Bruno Laugel, Joseph P. Sanderson, Andrew B. Gerry
Publikováno v:
Journal of Immunotherapy. 46:132-144
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7715cb90323ed54b3892df41acd3d2d
https://doi.org/10.1097/cji.0000000000000456
https://doi.org/10.1097/cji.0000000000000456
Autor:
Hartwig, Torsten, Montinaro, Antonella, von Karstedt, Silvia, Sevko, Alexandra, Surinova, Silvia, Chakravarthy, Ankur, Taraborrelli, Lucia, Draber, Peter, Lafont, Elodie, Arce Vargas, Frederick, El-Bahrawy, Mona A., Quezada, Sergio A., Walczak, Henning
Publikováno v:
In Molecular Cell 16 February 2017 65(4):730-742
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Philipp Beckhove, Viktor Umansky, Jürgen Weitz, Christoph Reissfelder, Christel Herold-Mende, Steffen Dettling, Helge Frebel, Florian Schuetz, Christoph Domschke, Alexandra Sevko, Andreas Bonertz, Michael Hillier, Christopher Breyer, Ludmila Umansky, Mudita Pincha, Xiaoying Hu, Maria Xydia, Anchana Rathinasamy, Hans-Henning Böhm, Yingzi Ge
Endogenous antitumor effector T-cell responses and immune-suppressive regulatory T cells (Treg) critically influence the prognosis of patients with cancer, yet many of the mechanisms of how this occurs remain unresolved. On the basis of an analysis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b45291cdb5c5112c0e94cccb89461c
https://doi.org/10.1158/2326-6066.c.6549904
https://doi.org/10.1158/2326-6066.c.6549904
Autor:
Philipp Beckhove, Viktor Umansky, Jürgen Weitz, Christoph Reissfelder, Christel Herold-Mende, Steffen Dettling, Helge Frebel, Florian Schuetz, Christoph Domschke, Alexandra Sevko, Andreas Bonertz, Michael Hillier, Christopher Breyer, Ludmila Umansky, Mudita Pincha, Xiaoying Hu, Maria Xydia, Anchana Rathinasamy, Hans-Henning Böhm, Yingzi Ge
Supplemental Figures S1 to S12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7395cd4ba0158d1981214789f1632607
https://doi.org/10.1158/2326-6066.22542394.v1
https://doi.org/10.1158/2326-6066.22542394.v1
Autor:
Viktor Umansky, Jochen Utikal, Dirk Schadendorf, Antje Sucker, Philipp Beckhove, Ludmila Umansky, Tim Holland-Letz, Kathrin Tarnanidis, Maike Reith, Ramtin Lichtenberger, Huanhuan Jiang, Alexandra Sevko, Christoffer Gebhardt
Multivariate logistic regression analysis of all possible predictive markers for response to Ipilimumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83c11c3efa3bb4a0934dd01f56b1a510
https://doi.org/10.1158/1078-0432.22461126.v1
https://doi.org/10.1158/1078-0432.22461126.v1
Autor:
Viktor Umansky, Jochen Utikal, Dirk Schadendorf, Antje Sucker, Philipp Beckhove, Ludmila Umansky, Tim Holland-Letz, Kathrin Tarnanidis, Maike Reith, Ramtin Lichtenberger, Huanhuan Jiang, Alexandra Sevko, Christoffer Gebhardt
Purpose: Immunotherapy with ipilimumab improves the survival of patients with metastatic melanoma. Because only around 20% of patients experience long-term benefit, reliable markers are needed to predict a clinical response. Therefore, we sought to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d3d31bd491a7c2ae7944eac4b0de8b
https://doi.org/10.1158/1078-0432.c.6524700
https://doi.org/10.1158/1078-0432.c.6524700